Press Releases

Press Releases

or

January 21, 2020
BEIJING, China , and CAMBRIDGE, Mass. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today
January 8, 2020
CAMBRIDGE, Mass. and BEIJING, China , Jan. 08, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today
December 13, 2019
- Oral presentation on data from Phase 1b trial in patients with platinum-resistant ovarian cancer CAMBRIDGE, Mass. and BEIJING, China , Dec. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and